Researchers have learned how to stimulate the immune system in animal models to produce large quantities of broadly neutralizing antibodies against HIV—a prerequisite for an effective vaccine.
Children born during the pandemic, including those exposed to COVID-19 in utero, were no more likely to screen positive for autism than unexposed or pre-pandemic children.
The 2024 Lasker-Bloomberg Public Service Award recognizes Quarraisha Abdool Karim and Salim S. Abdool Karim for global contributions to the fight against HIV/AIDS.
With $16 million gift, Columbia will open a new center for Lyme and other tick-borne diseases this summer, offering patients specialized care and expanding research at a national level.
SARS-CoV-2, the virus that causes COVID-19, does not infect brain cells but can inflict significant neurological damage, according to a new study of dozens of deceased patients.
With more patients complaining of lingering and chronic effects from COVID-19, Columbia experts review what’s known and why care for long-haulers requires an interdisciplinary approach.
Kellie Bryant, DNP, and Robert Fullilove, EdD, discussed myths and facts about the COVID-19 vaccine at a virtual event organized by the Williamsbridge branch of the NAACP.
A real-time study of immune responses inside the lungs of COVID patients suggests a cytokine “hurricane” in the airways drives severe disease, and an influx of T cells may be critical to survival.
New videos from Hip Hop Public Health, a community organization founded by a Columbia neurologist, are using the power of music to help increase COVID-19 vaccine coverage in communities of color.
Jessica Justman, MD, an infectious disease specialist and epidemiologist at Columbia, says vaccinated people still need to take some precautions for now.
A virtual town hall hosted by CUIMC and NewYork-Presbyterian Hospital brought together community health workers and local leaders to discuss questions and concerns regarding the COVID-19 vaccines.
New Columbia study suggests current vaccines and monoclonal antibody therapies provide less neutralizing activity against the U.K. and South Africa variants of SARS-CoV-2.